The Daily RFK Jr Antidepressants Episode Review: A Sharp, Uneasy Look at SSRIs, Deprescribing and the Patients Caught in Between

The Daily RFK Jr antidepressants episode lands in the uncomfortable space where public health policy, psychiatric medicine, political distrust and private suffering all collide. The New York Times podcast episode, titled “R.F.K. Jr.’s Newest Mission: Getting Us Off Antidepressants,” features host Michael Barbaro speaking with Ellen Barry, a New York Times mental health reporter, about Robert F. Kennedy Jr.’s push to make “deprescribing” psychiatric medication a federal health priority. Apple Podcasts lists the episode as a June 22, 2026 release, with a 32-minute runtime and Barry as the guest.

What makes the episode more than another RFK Jr. controversy segment is that it does not simply ask, “Is Kennedy right or wrong?” The sharper question is: Why has medicine become so good at starting antidepressants, but often so vague about stopping them? The uploaded transcript shows Barbaro and Barry moving between Kennedy’s provocative claims, the medical establishment’s alarm, patient stories about withdrawal, and Barbaro’s own candid admission that he has taken Lexapro for years without ever having a deep “how long should I stay on this?” conversation with a doctor.

That personal turn is what gives the episode its voltage. This is not a tidy anti-drug or pro-drug debate. It is about people who may need psychiatric medication, people who may no longer need it, people who cannot access therapy, doctors who lack time, patients who feel abandoned, and a federal health secretary whose rhetoric can spotlight a real problem while also risking a damaging oversimplification.

Episode at a glance

Apple Podcasts describes the episode as a look at Kennedy’s newest public health crusade and the broader medical “open secret” that doctors are often better at starting drug treatments than stopping them.

What happens in the episode?

The episode opens with a familiar Daily technique: a public policy question is made intimate through voices. Before the audience gets a policy memo, a statistic or a political framing, we hear patients describing long-term antidepressant use. One person says they have been on Zoloft since childhood. Another says they have been taking antidepressants for decades. The emotional framing is immediate: these are not abstract “users” in a prescribing database. They are adults asking whether a medication that once helped them has quietly become part of their identity, routine and fear.

Barbaro then introduces Ellen Barry, who explains the term deprescribing as the careful reduction or tapering of psychiatric medication. Barry’s reporting, as presented in the transcript, traces the movement partly to patient communities that have existed for years online. These forums and support groups have long discussed withdrawal symptoms, tapering schedules and frustration with doctors. What has changed, Barry says, is not that these patients suddenly appeared. It is that they now have a more direct route into federal policy because RFK Jr., as health secretary, has elevated the issue.

The first half of the episode walks listeners through Kennedy’s argument and his policy proposals. During his confirmation hearings and later public appearances, Kennedy questioned whether Americans are too freely and too permanently placed on psychiatric medications, especially SSRIs. The episode notes that he made the dramatic claim that SSRIs can be harder to quit than heroin. Barry plainly says there is no evidence supporting that comparison. That moment matters because the episode does not let Kennedy’s rhetoric float unchallenged. It separates the heat of the claim from the real issue underneath: some patients do struggle badly when trying to stop antidepressants.

From there, Barry explains the federal action. HHS announced a May 4, 2026 action plan to “curb psychiatric overprescribing,” promote appropriate prescribing and support deprescribing when clinically indicated. The plan included attention to informed consent, nonmedication approaches such as psychotherapy, nutrition and physical activity, reimbursement guidance for deprescribing-related care, education initiatives, and a planned technical expert panel to develop clinical guidance.

The episode then pivots to the reaction from psychiatry. Barry describes attending the American Psychiatric Association’s annual meeting, where she found two overlapping responses. Some psychiatrists feared that Kennedy’s campaign could stigmatize psychiatric medication or become a back door to restricting access. Others agreed that medicine has underinvested in the practical art of taking people off medications safely. The nuance is important: the episode does not frame psychiatry as monolithic. It shows a profession both defensive and self-critical.

In the second half, the episode becomes more patient-centered. Barry describes why some people want to stop taking antidepressants: emotional blunting, sexual side effects, a feeling that the drug no longer works, curiosity about who they might be without it, or the sense that a medication started in adolescence may not be the right default decades later. The transcript includes patients describing “brain zaps,” insomnia, crying spells and the destabilizing intensity of emotion after tapering or stopping.

Then Barbaro makes the conversation personal. He says he has taken Lexapro for anxiety for at least a decade and has not really been asked to think deeply about how long he should remain on it. He describes experiencing severe headaches when he failed to take it reliably, but not a broader medical conversation about whether tapering was appropriate. That confession changes the episode’s temperature. Suddenly the show is not merely reporting on a national debate. It is asking the same question many listeners may be quietly asking: Am I on this because I still need it, because it works, because stopping scares me, or because nobody ever reopened the conversation?

The episode ends with the necessary caution. Barry stresses that some people truly need antidepressants and that many communities still lack access to mental health care. CDC data from 2023 shows that 11.4% of U.S. adults took prescription medication for depression, with major differences by sex, race, income, disability status and geography. The episode’s final argument is not “get off antidepressants.” It is closer to: patients deserve both access to treatment and a serious plan for how to reassess that treatment over time.

The biggest talking points from the episode

RFK Jr. turns deprescribing into a federal issue

The episode’s central news hook is RFK Jr.’s attempt to move deprescribing from the margins of patient forums into federal policy. HHS framed its May 2026 action plan around appropriate psychiatric prescribing, patient autonomy, informed consent, shared decision-making and tapering when patients are not experiencing clinical benefit.

That framing is politically powerful because it borrows language almost everyone can support. Who opposes informed consent? Who opposes shared decision-making? Who wants patients to remain on medications that no longer help them?

But Barry’s reporting highlights the tension: Kennedy’s broader reputation and past comments make many medical professionals wary of where this conversation could go. There is a difference between saying, “We need better discontinuation support,” and implying that SSRIs are generally suspect, overused or comparable to addictive illicit drugs. The episode does a good job of holding both thoughts in view.

Kennedy’s policy push may be useful if it leads to better reimbursement, more research, clearer tapering guidance and more time for clinicians to help patients make informed decisions. It becomes risky if the public hears it as a message that antidepressants are inherently dangerous or that people should stop them on their own.

The “starting vs. stopping” problem in medicine

One of the best phrases in the episode is the idea that doctors are often better at starting treatments than stopping them. It is not limited to psychiatry. Modern medicine is built around diagnosis, intervention and prescription. The stop button is less glamorous, less reimbursed and often less clearly taught.

Barry explains that many psychiatrists receive far more training in prescribing than in deprescribing. That imbalance matters because antidepressant discontinuation can be medically and emotionally complicated. The episode notes that a typical medication check may be too short for a careful tapering conversation, especially when a patient has been on medication for years or takes several psychiatric drugs.

HHS’s action plan explicitly addresses part of this problem by pointing to billing and reimbursement pathways for deprescribing-related care. That may sound bureaucratic, but it is central. A healthcare system often does what it pays clinicians to do. If starting a prescription is fast and reimbursable, while tapering requires long conversations, monitoring and uncertainty, the system quietly favors continuation.

SSRIs are common, but long-term evidence remains thinner than many assume

The episode explains that SSRIs, including drugs such as Prozac, Zoloft and Lexapro, are widely used for depression, anxiety disorders, obsessive-compulsive disorder, PTSD and other conditions. The public sometimes talks about them as if their long-term use is fully mapped. Barry makes clear that the research picture is less complete.

Many antidepressant trials are short-term efficacy studies. Long-term real-world use is much harder to study. That creates a strange mismatch: millions of people take these drugs for years, while the strongest clinical trial evidence often concerns shorter treatment windows.

Recent data helps explain why the subject has become so charged. A 2026 BMJ Mental Health study reported current antidepressant use among 16.6% of surveyed U.S. adults, while CDC data for 2023 found that 11.4% of adults took prescription medication for depression. Those figures are not identical because they measure different things, but both point to the same reality: antidepressants are a major part of American mental health care.

The episode’s best move is that it does not confuse prevalence with misuse. A high number of prescriptions can mean overuse in some cases, under-access in others, and appropriate treatment in many more. Barry explicitly raises that problem near the end: some groups may be overexposed to medication-first care, while others are still only beginning to access mental health treatment at all.

The patient-led deprescribing world has been building for years

Barry describes online communities where patients share tapering experiences, compare withdrawal symptoms and discuss strategies such as reducing doses very gradually. That world can be both valuable and risky. It exists partly because patients feel abandoned. It also exists outside the safeguards of formal medical care.

The episode mentions people using forums, Reddit and other online spaces to figure out how to taper when their doctors cannot or will not provide detailed guidance. That detail is one of the episode’s quiet indictments of the system. When patients are using kitchen-table chemistry, bead counting, liquid formulations and peer advice to solve a medication problem, they are not necessarily rejecting medicine. They may be filling a gap medicine left open.

That does not mean DIY tapering is safe. Mayo Clinic notes that stopping antidepressants abruptly can cause symptoms such as dizziness, headache, nausea, agitation, anxiety, electric shock sensations, flu-like symptoms and insomnia. The Royal College of Psychiatrists advises gradual tapering and recommends discussing stopping plans with a doctor or pharmacist.

This is where the episode’s politics and its medical common sense overlap. Even people who distrust RFK Jr.’s broader agenda may agree that patients should not have to crowdsource withdrawal protocols because the healthcare system lacks time, training or practical tools.

Michael Barbaro’s Lexapro admission makes the episode unusually relatable

The most memorable moment is Barbaro’s disclosure that he has been on Lexapro for anxiety for at least a decade. It is not treated as a dramatic confession. It is more interesting than that. He speaks like someone realizing, in real time, that the question he is reporting on has been sitting in his own medicine cabinet.

That moment gives the episode moral complexity. Barbaro is not mocking patients who want off medication, nor is he positioning himself above them. He is inside the question. He says the drug became part of his relationship with his general practitioner. He gets renewals. He has experienced symptoms when he misses doses. But the deeper conversation about duration, tapering and whether his anxiety would return has not happened.

That is exactly the kind of experience the episode is about. Not crisis. Not malpractice. Not a villainous doctor. Just a treatment that continues because continuation is the path of least resistance.

The access problem complicates the overprescription debate

Near the end, Barry introduces a crucial counterweight: many Americans who could benefit from psychiatric care still do not get it. She notes that antidepressant use varies sharply by demographic group. CDC data similarly shows significant differences by race and Hispanic origin, disability status, income, living arrangement and region. In 2023, White non-Hispanic adults were more likely to report taking medication for depression than Black, Hispanic, Asian, and American Indian or Alaska Native non-Hispanic adults; Asian non-Hispanic adults had the lowest reported rate among the listed groups.

This matters because a single national message — “America is overmedicated” — can flatten very different realities. A suburban adult with easy access to primary care may have been renewed on an SSRI for years with little review. Another person may be struggling with untreated depression because therapy is unaffordable, psychiatrists are unavailable, stigma is high, or primary care is the only mental health doorway they have.

The episode’s most responsible idea is that both conversations need to happen: how to get people treatment when they need it, and how to help people stop or reduce treatment when they no longer do.

The most memorable moments

The first memorable moment is Kennedy’s heroin comparison. The episode handles it with a firm correction: Barry says there is no evidence that SSRIs are harder to quit than heroin. That brief exchange matters because it prevents the episode from drifting into false equivalence. The public debate around SSRIs is already emotionally loaded. Bad comparisons can frighten people who need medication and anger people who have suffered through withdrawal.

The second memorable moment is the description of patients tapering with extreme precision. The image of people reducing medication by tiny amounts, sometimes bead by bead, is striking because it shows how far patient communities have gone to create practical methods where formal care may be lacking.

The third is the “brain zaps” section. It is a phrase many people have heard online, but the episode makes it concrete: an electric, shock-like sensation in the head that some patients experience while stopping or reducing antidepressants. Mayo Clinic also lists electric shock sensations among possible antidepressant withdrawal symptoms.

The fourth is Barbaro’s personal Lexapro moment. It feels like the episode’s hinge. Until then, the story is about patients, doctors and RFK Jr. After that, it becomes about the ordinary silence around long-term medication.

The fifth is Barry’s final caution: if the message becomes too anti-medication, people who need care may never start treatment. That is the episode’s most important guardrail.

About the podcast

The Daily is one of the defining news podcasts of the streaming era. Apple Podcasts describes it as a show that tells “the biggest stories of our time” through New York Times journalists, hosted by Michael Barbaro, Rachel Abrams and Natalie Kitroeff, with a daily news format built for weekday listening.

The show’s identity is simple but difficult to execute: take one major story, slow it down, and make the reporting feel conversational without making it shallow. Rather than giving listeners a pile of headlines, The Daily often picks one subject and builds a narrative arc around it. A typical episode uses a Times reporter as guide, with Barbaro or another host playing the role of curious listener, skeptic and translator.

This antidepressants episode fits the show’s format well. It starts with human voices, introduces a policy question, brings in a reporter with domain knowledge, complicates the obvious partisan reading, and ends by widening the lens. It also includes the show’s familiar “Here’s what else you need to know today” news brief near the end, a structural signature for The Daily.

What sets this episode apart is Barbaro’s personal disclosure. The Daily can sometimes sound carefully polished, even theatrical. Here, the polish cracks in a useful way. The host becomes part of the story without taking it over.

About Ellen Barry and the central subject

Ellen Barry is identified by Apple Podcasts as a New York Times reporter covering mental health and as the guest for this episode. In the conversation, she functions less as a pundit and more as a careful mapmaker. Her role is to explain where Kennedy’s policy push came from, why psychiatrists are worried, why some patients feel vindicated, and why the issue resists a clean ideological sorting.

The central subject is deprescribing, especially in relation to SSRIs. Deprescribing is not simply “quitting medication.” It refers to reviewing whether a medication remains useful, reducing or discontinuing it when clinically appropriate, and doing so with care. In psychiatric medication, that can mean slow tapering, monitoring for withdrawal symptoms, watching for relapse, and adjusting the plan based on the patient’s response.

The political subject is Robert F. Kennedy Jr., whose health secretary role gives the topic federal force. HHS’s May 2026 plan says the department wants to prevent unnecessary initiation of psychiatric medications and support tapering or discontinuation for patients who are not receiving clinical benefit.

The medical subject is more complicated: SSRIs can be enormously helpful for some patients, insufficient for others, and difficult to stop for a subset. The episode’s value lies in refusing to pretend one of those truths cancels out the others.

The larger context behind the conversation

The larger context is not simply “America takes too many antidepressants.” That phrase is too crude. The real context is a mental health system that often uses medication as the most available tool because other tools are slower, more expensive or harder to access.

Therapy takes time. Lifestyle changes require support and stability. Social connection cannot be prescribed in a 15-minute appointment. Sleep, nutrition and exercise matter, but they are not magic replacements for clinical treatment. Primary care doctors are often the front line for mental health because psychiatrists are scarce, waitlists are long and insurance networks are frustrating.

That is why antidepressants occupy such a strange position in American life. They are medical treatments, cultural symbols, political targets, personal lifelines and sometimes sources of ambivalence. One person’s SSRI is what allows them to work, parent and survive. Another person’s SSRI is a drug they started at 16 and still renew at 35 without knowing whether it remains necessary.

HHS’s action plan reflects some of this complexity by emphasizing informed consent, nonmedication options, reimbursement for deprescribing-related care and future clinical guidance. But the public debate around Kennedy rarely stays that careful. His critics worry that his language can stigmatize psychiatric medication. Reuters reported that the American Psychiatric Association objected to framing the mental health crisis primarily as overmedicalization or overprescribing, while supporting better research and better prescribing/deprescribing decisions.

The episode also arrives during a broader cultural shift. More patients are talking publicly about emotional blunting, sexual side effects, withdrawal, overdiagnosis, ADHD medication, therapy culture and what it means to treat distress medically. Some of that discussion is sophisticated. Some is reckless. The Daily’s episode works because it does not pretend the internet patient movement is either nonsense or gospel. It treats it as evidence that a need has gone unmet.

What the episode gets right

The episode’s biggest strength is balance without blandness. It does not split the difference lazily. It says Kennedy’s heroin comparison lacks evidence, but it also says the withdrawal problem is real for some patients. It says SSRIs can be life-changing, but it also asks why long-term use often continues without structured reassessment.

Barry is especially strong at distinguishing policy from rhetoric. HHS’s actual plan includes some reasonable-sounding components: informed consent, shared decision-making, nonmedication treatment options, reimbursement guidance and expert panels. Kennedy’s rhetoric, however, carries a different charge. The episode lets listeners hear both.

The patient stories also work. They are specific enough to humanize the topic but not used as proof that every patient should stop medication. That distinction is essential. In health journalism, anecdotes can either illuminate or distort. Here, they mostly illuminate.

Barbaro’s personal turn is another strength. It could have become self-indulgent. Instead, it sharpens the stakes. He models the exact uncertainty many listeners may feel: if a drug helped me once, does that mean I should remain on it forever? If I feel bad when I miss it, is that withdrawal, relapse, dependence, fear or some mix of all four? Those are not easy questions, and the episode does not insult listeners by pretending they are.

Finally, the episode’s ending is responsible. It clearly warns against a one-size-fits-all message. That matters because psychiatric medication is not a culture-war prop to the people taking it. It is part of their daily life.

What could have been better

The episode could have spent more time on the practical difference between withdrawal and relapse. It mentions the distinction, but this is one of the hardest issues for patients and clinicians. If someone feels anxious, sleepless or emotionally overwhelmed after reducing an SSRI, are they experiencing withdrawal symptoms, a return of the original condition, or both? That question deserves more time.

The episode also could have explained more clearly what good deprescribing care looks like. Listeners hear about slow tapers, doctor supervision and patient forums, but a more concrete framework would have helped: medication review, symptom history, prior relapse episodes, taper schedule, monitoring intervals, support plan, and what to do if symptoms become severe. The Royal College of Psychiatrists emphasizes gradual tapering and individualized reduction plans, which would have been useful context for a general audience.

The episode might also have benefited from more direct voices from practicing psychiatrists. Barry summarizes what she heard at the APA meeting, but a clip from a clinician who supports deprescribing and a clinician worried about access could have added texture.

Finally, while the show is careful about Kennedy’s rhetoric, it could have more sharply explored the political incentives behind the issue. Deprescribing is a legitimate medical topic. It is also a convenient political story because it lets Kennedy criticize pharmaceutical culture, medical authority and overmedicalization all at once. The episode gestures toward that but does not fully dissect it.

How listeners are reacting

Public reaction appears active but still early. Reddit discussion threads have appeared in both r/Thedaily and r/Psychiatry, with the latter framing the episode around concerns about how The New York Times covers healthcare and whether the episode gave enough clinical context.

That split is predictable. General listeners may respond to the patient stories and Barbaro’s personal disclosure. Clinicians and medically informed readers may focus on whether the episode sufficiently distinguishes withdrawal from relapse, access from overuse, and Kennedy’s rhetoric from evidence-based deprescribing.

The episode’s likely audience reaction falls into three camps:

First, patients who have struggled to stop antidepressants may feel seen. The episode validates the idea that withdrawal can be difficult and that many people have felt unsupported.

Second, patients who rely on SSRIs may feel uneasy. Any national conversation about “getting us off antidepressants” can sound threatening, especially to people who remember how bad life felt before treatment.

Third, clinicians may have mixed feelings. Many will agree that deprescribing deserves more attention. Many will also worry that political pressure could frighten patients away from effective care.

Because the episode was only released on June 22, 2026, broad public reaction is still developing.

Is this episode worth listening to?

Yes — especially if you want a thoughtful overview of the antidepressant deprescribing debate without being pushed into a simplistic conclusion.

This episode is best for listeners who care about mental health policy, SSRIs, RFK Jr., patient autonomy, psychiatry, or the everyday experience of long-term medication. It is also worth hearing if you have ever taken an antidepressant and wondered whether anyone is supposed to help you decide when, whether or how to stop.

It may be less satisfying for listeners who want a technical medical guide. The episode is journalism, not clinical advice. It does not tell anyone whether to start, stop or taper medication. Nor should it. Anyone considering changing antidepressant use should speak with a qualified clinician; medical sources consistently warn against abrupt stopping and recommend gradual tapering under guidance.

As a podcast episode, though, it succeeds. It explains the controversy, complicates the politics, humanizes the patients and gives Barbaro one of his more personally revealing moments in recent Daily memory.

Best quotes and ideas from the episode

The strongest idea is the “landing the plane” metaphor: medicine often puts more effort into takeoff than landing. Starting treatment gets attention. Stopping treatment requires time, patience and uncertainty.

Another key idea is that the antidepressant debate cannot be reduced to one message for the whole country. Some patients may be on medication longer than needed. Others cannot access treatment at all. Both realities can be true.

The episode also lands on a quietly radical question: Should doctors be the ones to reopen the conversation about long-term medication, or should patients be expected to ask first? The answer should probably be both. But the fact that so many patients say the conversation never happens suggests the system has work to do.

Final verdict

The Daily RFK Jr antidepressants episode is one of the show’s stronger health-policy conversations because it resists the easiest version of the story. It does not make RFK Jr. the hero of deprescribing. It does not make psychiatry the villain. It does not treat SSRIs as either miracle drugs or chemical traps. Instead, it asks why a medication class used by millions can be started so casually in some settings and stopped with so little structured support.

Ellen Barry brings clarity to a messy subject. Michael Barbaro brings curiosity and, unexpectedly, vulnerability. The patient voices bring urgency. The result is a podcast episode that will probably make some listeners uncomfortable in exactly the right way.

The episode matters because it identifies a genuine failure point in modern medicine: the missing follow-up conversation. Not every patient should stop antidepressants. Not every patient should stay on them indefinitely. The point is that patients deserve more than automatic refills and vague advice. They deserve evidence, time, monitoring and a real conversation about what treatment is doing for them now.

For PodcastCharts.net readers, this is a highly recommended listen — not because it answers every question, but because it asks the one many people have been avoiding.

FAQ

What is The Daily RFK Jr antidepressants episode about?

It is about Robert F. Kennedy Jr.’s push to make antidepressant deprescribing a federal health priority, especially for SSRIs. The episode explores patient withdrawal stories, psychiatric concerns, HHS policy proposals and the larger question of whether doctors spend enough time helping patients stop medications safely.

Who is the guest on this episode of The Daily?

The guest is Ellen Barry, a New York Times reporter covering mental health. Apple Podcasts identifies Barry as the episode guest.

Who hosts the episode?

Michael Barbaro hosts this episode. The broader show is hosted by Michael Barbaro, Rachel Abrams and Natalie Kitroeff, but this specific conversation is led by Barbaro.

When was the episode published?

The episode was published on June 22, 2026, according to Apple Podcasts.

How long is the episode?

Apple Podcasts lists the episode runtime as 32 minutes.

What are SSRIs?

SSRIs, or selective serotonin reuptake inhibitors, are a widely used class of antidepressants. Common examples include Prozac, Zoloft and Lexapro. They are prescribed for depression and several anxiety-related conditions.

Does the episode say SSRIs are bad?

No. The episode is more nuanced than that. It says SSRIs can help many people, but it also examines whether some patients stay on them for years without enough review, guidance or support for tapering.

Does RFK Jr. want people to stop taking antidepressants?

The episode discusses Kennedy’s push for deprescribing when clinically appropriate. HHS’s official action plan says it aims to prevent unnecessary initiation of psychiatric medications and support tapering or discontinuation for patients not experiencing clinical benefit.

Is antidepressant withdrawal real?

Yes, antidepressant discontinuation symptoms are recognized by medical sources. Mayo Clinic lists possible symptoms including dizziness, headaches, nausea, anxiety, electric shock sensations, flu-like symptoms and insomnia.

Should listeners stop antidepressants after hearing the episode?

No. The episode should not be treated as medical advice. People considering stopping or reducing antidepressants should speak with a qualified healthcare professional and avoid abrupt changes unless directed by a clinician.

What is the best part of the episode?

The best part is Michael Barbaro’s personal reflection on taking Lexapro for years without a deeper conversation about duration or tapering. It transforms the episode from a policy discussion into something many listeners may recognize in their own lives.

Is this episode worth listening to?

Yes. It is a timely, careful and human episode about a topic that is likely to become even more prominent in mental health policy and podcast discussion.